))
How are GMO Regulations Impacting Clinical Development in Europe?
Manage episode 414564352 series 3517729
Content provided by Boyds. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Boyds or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this episode of Conversations in Drug Development, our host Harriet Edwards, is joined by Director of Regulatory Affairs, Dr Sabine Ruehle, to discuss the challenges of navigating genetically modified organism (GMO) regulations in clinical trials within Europe. This discussion helps decipher the nuanced environment of GMOs and their associated risks unique within the European framework. Join us as we explore the outdated definition of GMOs, the complexities of their classification, and the impact of genome editing technologies.
10 episodes
Share
